Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Grifols SA (GRFS – Research Report) and Cochlear Limited (CHEOF – Research Report).
Grifols SA (GRFS)
Kepler Capital analyst Pablo de Renteria maintained a Buy rating on Grifols SA on July 4 and set a price target of EUR17.50. The company’s shares closed last Wednesday at $9.19.
Renteria has an average return of
According to TipRanks.com, Renteria is ranked #8036 out of 8499 analysts.
Grifols SA has an analyst consensus of Moderate Buy, with a price target consensus of $17.13.
See Insiders’ Hot Stocks on TipRanks >>
Cochlear Limited (CHEOF)
Jarden analyst Steven Wheen maintained a Hold rating on Cochlear Limited yesterday and set a price target of A$218.09. The company’s shares closed last Monday at $150.23.
According to TipRanks.com, Wheen is a 4-star analyst with an average return of
Cochlear Limited has an analyst consensus of Moderate Sell, with a price target consensus of $147.40, which is a -1.9% downside from current levels. In a report issued on June 23, RBC Capital also maintained a Hold rating on the stock with a A$219.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GRFS:
